Back to the future: Antibody-based strategies for the treatment of infectious diseases

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 21, Issue 3, 2002, Pages 225-239

  Oral, H Barbaros ^a   Akdiş, Cezmi A ^b   Özakin, Cüneyt ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

Antibody therapy; Immunoglobulin; Infectious diseases

Indexed keywords

BACTERIUM ANTIBODY; MONOCLONAL ANTIBODY; VIRUS ANTIBODY; ANTIBODY; CENTOXIN; CHICKENPOX VACCINE; CYTOMEGALOVIRUS VACCINE; DIPHTHERIA ANTIBODY; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN; INTERLEUKIN 6 ANTIBODY; MEASLES VACCINE; MUMPS VACCINE; NEUTRALIZING ANTIBODY; RABIES VACCINE; RUBELLA VACCINE; TETANUS ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL; BACTERIAL INFECTION; HUMAN; IMMUNOTHERAPY; INFECTION; REVIEW; VIRUS INFECTION; ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIMICROBIAL ACTIVITY; ASEPTIC MENINGITIS; DRUG COST; DRUG RESEARCH; DRUG USE; KIDNEY FAILURE; NONHUMAN; THROMBOEMBOLISM;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; BACTERIAL INFECTIONS; HUMANS; IMMUNOTHERAPY; INFECTION; VIRUS DISEASES; ANIMAL; HUMAN;

ANIMALIA; BACTERIA (MICROORGANISMS); CYTOMEGALOVIRUS;

EID: 0036634582     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:21:3:225     Document Type: Review

References (114)

1. Summary of Antibody workshop: The role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases
2. "Serum therapy" revisited: Animal models of infection and the development of passive antibody therapy
3. The units of protective antibody in anti-pneumococcus serum and antibody solution
4. Human immunoglobulins for intravenous use and hepatitis C viral transmission
5. Antibody-based therapies for emerging infectious diseases
6. Continuous cultures of fused cells secreting antibody of predefined specificity
7. Monoclonal antibodies in diagnosis and therapy
8. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia
9. Treatment of septic shock with human monoclonal antibody HA-1A
10. A controlled trial of HA-1A in a canine model of gram-negative septic shock
11. The French National Registry of HA-1A (Centoxin) in septic shock
12. The immune response to infection
13. Antibodies
14. Standard and special human immune serum globulins as therapeutic agents
15. Titered lots of immune globulin. Efficacy in the prevention of rubella
16. Eficacy of immune serum globulin in an outbreak of hepatitis A virus infection in adults
17. The prevention and attenuation of infectious hepatitis by gamma globulin
18. Immunoglobulin prophylaxis for hepatitis A
19. Hepatitis B immunoglobulin in prevention of HBs antigenemia in haemodialysis patients
20. Hepatitis B immune serum globulin and standard gamma globulin in prevention of hepatitis B infection among hospital staff: A preliminary report
21. Immune globulins for protection against viral hepatitis
22. Passive-active immunity from hepatitis B immune globulin. Reanalysis of a Veterans Administration cooperative study of needlestick hepatitis
23. Hepatitis B immune globulin for accidental exposures among medical personnel: Final report of a multicenter controlled trial
24. Recommendation for protection against viral hepatitis
25. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immunoglobulin and hepatitis B vaccine
26. Varicella zoster immune globulin for the prevention of chickenpox: Recommendations of the immunization practices advisory committee
27. A study on the prevention of mumps orchitis with gamma globulin
28. Pathogenesis and prophylaxis of rabies in man
29. Purified equine rabies immune globulin: A safe and affordable alternative to human rabies immune globulin
30. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia alter bone morrow transplantation
31. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial
32. Clostridium tetani
33. Adequacy of anti-tetanus prophylaxis in six hospital emergency rooms
34. Corynebacterium diphtheriae
35. Invasive group A streptococcal infections in Ontario, Canada
36. Opsonic antibodies to the surface of group A streptococci in pooled normal immunoglobulins (IVIG): Potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections
37. Intravenous immunoglobulin therapy for toxic shock syndrome
38. Septic shock induced by group A streptococcal infection: Clinical and therapeutic aspects
39. Treatment with bovine hyperimmune colostrum of cryptosporodial diarrhea in AIDS patients
40. Neutralizing monoclonal antibody protects against Cryptosporidium parvum infection by inhibiting sporozoite attachment and invasion
41. Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merazoites
42. Enteral human serum immunoglobulin treatment of cryptosporidosis in mice with severe combined immunodeficiency
43. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS
44. Effect of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome
45. Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex
46. Passive immunotherapy in AIDS: A double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma
47. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type I gp120
48. A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity
49. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody
50. Synergistic neutralization of human immunodeficiency virus type-1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding sites
51. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals
52. Human antibodies to HIV-1 by recombinant DNA methods
53. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp 120 isolated by using an epitope-masking procedure
54. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity
55. Endotoxemia in human septic shock
56. Detection of circulating tumor necrosis factor after endotoxin administration
57. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways
58. Protection against gram-negative bacteraemia and endotoxemia with human monoclonal IgM antibodies
59. Treatment of gram-negative bacteraemia and septic shock with HA-1A human monoclonal antibody against endotoxin
60. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumour necrosis alfa and interleukin-6
61. Influence of alterations in foregoing life-sustaining treatment practice on a clinical sepsis trial
62. Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide
63. Chracterization of specific binding of a human immunoglobulin M monoclonal antibody to lipopolysaccharide and its lipid A domain
64. Human antilipid A monoclonal antibodies bind to human B cells and the i antigen on cord red blood cells
65. Anti-endotoxin human monoclonal antibody A6H4C5 (HA-1A) utilizes the VH4.21 gene
66. Anti-lipid A monoclonal antibody Centoxin (HA-1A) binds to a wide variety of hydrophobic ligands
67. Cytokines and sepsis: What are the therapeutic implications?
68. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin
69. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
70. Antibodies to cachetic/tumor necrosis factor reduce interleukin-1β and interleukin 6 appearance during lethal bacteraemia
71. Divergent efficacy of antibody to tumor necrosis factor α in intravascular and peritonitis models of sepsis
72. Potential treatment of sepsis syndrome with cytokine-specific agents
73. Antitumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation puncture or endotoxemia
74. Dosage and timing of anti-TNF-alpha antibody treatment determine its effect of resistance to sepsis after injury
75. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis
76. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment. MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
77. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-α challenge in mice
78. Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies
79. In the mouse the activation of the hypothalamic-pituatry-adrenal axis by lipopolysaccharide is mediated through interleukin-1
80. In vivo modulation with interleukin-1 receptor antibody 35F5 of the response to IL-1: The relationship of radioprotection, colony stimulating factor, and IL-6
81. Inhibition of interleukin 1 binding and bioactivity in vivo and modulation of acute inflammation in vivo by IL-1 receptor antagonists and anti-IL-1 receptor monoclonal antibody
82. New therapeutic targets revealed through investigations of innate immunity
83. Extolling the diversity of bacterial endotoxins
84. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin
85. Return to the past: The case for antibody-based therapies for infectious diseases
86. Therapeutic effects of a human anti-flagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia
87. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophilaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children
88. Monoclonal antibodies in sepsis and septic shock
89. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: Enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies
90. Immune enhancement of viral infection
91. Intracellular neutralization of virus by immunoglobulin A antibodies
92. A monoclonal antibody that inhibits intracellular replication
93. Intrabodies: Turning the humoral immune system outside in for intracellular immunization
94. A randomized trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus
95. Intravenous treatment of meningococcic meningitis with meningococcus antitoxin
96. Treatment of Haemophilus influenzae infections and of meningococcic and pneumococcic meningitis
97. Blood-brain barrier transport of cationized immunoglobulin G: Enhanced delivery compared to native protein
98. Anti-transferrin receptor antibody and antibody drug conjugates cross the blood-brain barrier
99. Cytokine immunotrapping: An assay to study the kinetics of production and consumption or degradation of human interferon-g
100. Immunotherapy with human monoclonal antibodies fragment: A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin
101. Aseptic meningitis is associated with high dose intravenous immunoglobulin therapy: Frequency and risk factors
102. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy: A study of the American Bone Marrow Transplantation Group
103. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants
104. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis
105. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy
106. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response
107. Humanized monoclonal antibody therapy for rheumatoid arthritis
108. Antibody-resistant mutants of Borrelia burgdorferi: In vitro selection and characterization
109. Mosaic-like organization of IgA protease genes in Neissseria gonorrhoeae generated by horizontal genetic exchange in vivo
110. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients: A trial of gancyclovir vs. immunoglobulin
111. The HA-1A monoclonal antibody for gram negative sepsis